| Abstrakt: |
A recent study conducted at the City of Hope National Medical Center in Duarte, California, has focused on the challenges of treating acute myeloid leukemia (AML) and the resistance of leukemia stem cells (LSCs) to treatment. The researchers found that interferon gamma (IFN-gamma) can reduce the clonogenic activity of LSCs and induce the upregulation of CD38 expression. They developed a novel T-cell engager called BN-CD38, which effectively eliminated leukemia cells in an autologous setting without affecting normal hematopoietic stem cells. This study provides important insights into targeting and eliminating AML LSCs. [Extracted from the article] |
